Angiotensin-receptor blockers in the prevention or treatment of microalbuminuria

Annals of Internal Medicine

Volumn 151, Issue 1, 2009, Pages 63-65

  Parfrey, Patrick S ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CANDESARTAN; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLICLAZIDE; INDAPAMIDE PLUS PERINDOPRIL; LISINOPRIL; RAMIPRIL; TELMISARTAN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG WITHDRAWAL; EDITORIAL; HEART DEATH; HEART INFARCTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; STROKE;

EID: 67650034662     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-151-1-200907070-00011     Document Type: Editorial

References (18)

1. U.S. Renal Data System. USRDS 2007 Annual Data Report. Bethesda, MD: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease; 2007.
2. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982;1:1430-2. [PMID: 6123720]
3. Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed). 1987;294:1651-4. [PMID: 3113569]
4. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med. 1997;157:1413-8. [PMID: 9224218]
5. Strippoli GF, Craig M, Schena FP, Craig JC. Antihypertensive agents for primary prevention of diabetic nephropathy. J Am Soc Nephrol. 2005;16:3081-91. [PMID: 16135776]
6. Bilous R, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes. Three randomized trials. Ann Intern Med. 2009;151:11-20.
7. Mann JF, Schmeider RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, et al; TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Effects of telmisartan on renal outcomes. A randomized trial. Ann Intern Med. 2009;151:1-10.
8. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al; DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372:1394-402. [PMID: 18823656]
9. Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al; DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372:1385-93. [PMID: 18823658]
10. Mitchell P, Wong TY. DIRECT new treatments for diabetic retinopathy. Lancet. 2008;372:1361-3. [PMID: 18823657]
11. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet. 1997;349:1787-92. [PMID: 9269212]
12. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355:253-9. [PMID: 10675071]
13. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941-51. [PMID: 15516697]
14. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-40. [PMID: 17765963]
15. Burgess E, Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S; SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 2009;20:893-900. [PMID: 19211712]
16. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-83. [PMID: 18757085]
17. de Zeeuw D. Targeting proteinuria as a valid surrogate for individualized kidney protective therapy [Editorial]. Am J Kidney Dis. 2008;51:713-6. [PMID: 18436079]
18. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-53. [PMID: 18707986]